NCT05621005View on ClinicalTrials.gov

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

July 1, 2022

Study Completion Date

August 1, 2022

Conditions

Ascites Infection

Interventions

DRUG

Rifaximin 550 milligram Oral Tablet [XIFAXAN]

Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months

Trial Locations (1)

02

faculty of medicine Ain Shams university, Cairo

All Listed Sponsors

lead

Samar Atef Sebaweh Mohammed

OTHER

NCT05621005 - Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients | Biotech Hunter | Biotech Hunter